Kognitic’s AI Model Revolutionizes Primary Completion Date Predictions for Clinical Trials

Key Takeaways:

• Kognitic’s AI reduces prediction errors from 508 to 179 days
• Analyzes data from over 60,000 oncology clinical trials
• PCD delays cost companies $600,000 to $8 million daily
• Adopted by leading pharmaceutical companies via SaaS subscriptions
• Study published in Foresight’s Q1 2025 edition

Revolutionizing Clinical Trial Timelines

A recent study published in Foresight highlights a significant advancement in clinical trial management: Kognitic’s AI neural network model has reduced primary completion date (PCD) prediction errors from a median of 508 days to just 179 days. This 65% improvement marks a transformative step for pharmaceutical companies striving to streamline drug development processes.

The Cost of Delay

Clinical trial delays are not just a matter of time—they carry hefty financial burdens. With PCD setbacks costing pharmaceutical companies between $600,000 to $8 million per day, the stakes are exceedingly high. Traditionally, sponsors’ initial PCD estimates have been off by a median of 508 days, leading to substantial unplanned expenditures and resource misallocation.

Harnessing Data from 60,000 Trials

Kognitic’s AI model tackles this challenge head-on by analyzing data from over 60,000 oncology clinical trials. The neural network considers multiple factors, including indication, phase, line of therapy, population, biomarkers, and other trial characteristics to generate more accurate predictions. This comprehensive approach enables the model to identify patterns and variables that influence trial timelines, which might be overlooked by traditional methods.

Industry Adoption Through SaaS Integration

Recognizing the potential for immense cost savings and efficiency gains, several leading pharmaceutical companies have integrated Kognitic’s PCD prediction model into their competitive intelligence and timeline management processes via SaaS subscriptions. This integration allows companies to make informed decisions about resource allocation, anticipate competitors’ market entries, and refine their drug development strategies with higher confidence.

Published Insights in Foresight

The study, titled “Neural Network Models to Predict Clinical Trial Completion,” appears in Foresight’s Q1 2025 edition. It details the methodology and findings of Kognitic’s research, underscoring the model’s ability to outperform traditional prediction methods significantly. The publication in a reputable journal adds credibility to the study and signals a noteworthy development in the field of predictive analytics.

Transforming Drug Development

By reducing prediction errors and enhancing planning accuracy, Kognitic’s AI model offers a promising solution to one of the pharmaceutical industry’s most pressing challenges. As companies continue to adopt this technology, the potential for accelerated drug development and more efficient market entry grows, ultimately benefiting not just the businesses but also the patients awaiting new therapies.

About Kognitic

Kognitic is a SaaS-based predictive intelligence platform revolutionizing how pharmaceutical and biotech companies approach competitive intelligence and business development. Utilizing advanced machine learning and natural language processing, Kognitic delivers real-time, actionable insights from clinical trials, drug pipelines, and market dynamics. Top pharmaceutical companies rely on Kognitic’s AI-powered analytics to transform weeks of analysis into minutes of intelligence.

For more information or to request a demo, visit kognitic.com or email